Eluminex Biosciences
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $40M
Overview
Develops innovative biologic therapies for sight-threatening eye diseases and immune-mediated inflammatory conditions.
OphthalmologyImmunology
Technology Platform
A protein engineering platform focused on designing biologics with optimized properties for treating ophthalmic and inflammatory diseases.
Funding History
1Total raised:$40M
Series A$40M
Opportunities
Large and growing market for geographic atrophy treatments where current options have significant limitations, creating demand for better therapies.
Risk Factors
Clinical failure risk in Phase 2/3 trials for lead program and intense competition from larger, well-resourced ophthalmology companies.
Competitive Landscape
Operates in the highly competitive retinal disease market, competing against approved complement inhibitors and other biologics, requiring clear differentiation on efficacy or safety.